Cotronak (ribavirin)
- Region
- 🇪🇺 EU
- Active substance
- ribavirin
- Company
- Schering-Plough Europe
- Status
- Withdrawn
- Therapeutic area
- Hepatitis C, Chronic
- EU approval
- Fri 07 May 1999
- Application
- EMEA/H/C/000247
- ATC
- J05AB04
- Official record
- www.ema.europa.eu
Indication
Cotronak is indicated for the treatment of chronic hepatitis C and must only be used as part of a combination regimen with peginterferon alfa-2b or interferon alfa-2b. Cotronak monotherapy must not be used.There is no safety or efficacy information on the use of Cotronak with other forms of interferon (i.e., not alfa-2b).Please refer also to the peginterferon alfa-2b or interferon alfa-2b Summary of Product Characteristics (SPC) for prescribing information particular to that product.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Rebetol Withdrawn · Merck Sharp and Dohme B.V
- 🇪🇺 Ribavirin Mylan (previously Ribavirin Three Rivers) Withdrawn · Mylan S.A.S
- 🇪🇺 Ribavirin Teva Withdrawn · Teva B.V.
- 🇪🇺 Ribavirin Teva Pharma B.V. Withdrawn · Teva B.V.
- 🇪🇺 Ribavirin BioPartners Lapsed · BioPartners GmbH
Follow Cotronak
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.